How to access Altuviiio from India — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian patient with Hemophilia A — particularly one on thrice-weekly or alternate-day standard factor VIII prophylaxis with residual breakthrough bleeds or a high infusion burden — may receive a prescription for Altuviiio (efanesoctocog alfa) from their treating haematologist. Altuviiio is FDA-approved, developed by Sanofi and Sobi, and is a first-in-class once-weekly extended-half-life factor VIII built as an Fc-VWF-XTEN fusion that extends circulating half-life well beyond conventional and earlier extended-half-life factor VIII products. In India, Altuviiio may not yet be broadly available through local distribution for every patient who clinically qualifies, which is why your haematologist may be navigating a named-patient import pathway with you.
This guide explains the legal pathway, what your haematologist needs to provide, typical timelines, and where Reserve Meds fits in.
The clinical situation
Altuviiio is administered as a once-weekly intravenous infusion, contrasting with standard factor VIII products that typically require infusion every two to three days and earlier extended-half-life products that require infusion every three to five days. The labelled indication covers routine prophylaxis, on-demand treatment of bleeding, and perioperative management in adults and children with Hemophilia A. Eligibility is clinical and based on your haematologist's assessment of bleed phenotype, adherence to current prophylaxis, inhibitor status, and response to prior factor VIII therapies. Reserve Meds does not participate in the clinical decision.
Is Altuviiio legally importable into India?
Yes — through the Central Drugs Standard Control Organisation (CDSCO) personal-import and named-patient import framework, with the standard operating constraint that the requesting physician takes clinical responsibility and the importing chain of custody is documented end to end.
The named-patient / personal import mechanism allows an Indian-licensed physician or the patient (with physician prescription) to import a medicine not locally marketed when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no locally available alternative is clinically equivalent for this patient, (c) the physician takes clinical responsibility, and (d) the importing party documents chain of custody. CDSCO reviews the application through the established import-licence route.
How the pathway works, step by step
- Consultation with your treating haematologist. Clinical rationale for Altuviiio documented in writing, including bleed history, current prophylaxis regimen, and response.
- Import authorisation application. Your physician or the importing pharmacy files the CDSCO personal-import / named-patient documentation.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Cold-chain shipment. Temperature-controlled transport with documented chain of custody.
- Arrival and infusion. Administered per your haematologist's protocol; either at a day-care infusion setting or as home-infusion where locally supported.
- Ongoing coordination. Reserve Meds supports re-supply cadence aligned to the once-weekly regimen.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming diagnosis, prior regimen, and Altuviiio as the indicated therapy
- Verification of their Indian medical licence
- Patient identifier (anonymised reference where possible)
- Prescription and dosing plan aligned to weight-based once-weekly dosing
- Planned administration setting
Reserve Meds provides a physician documentation kit that bundles the templates CDSCO reviewers expect to see.
Costs and timing
Altuviiio's US cash-pay list price varies by patient weight and dose; indicative monthly cost at typical adult prophylactic dosing falls in a broad range with the extended dosing interval partially offsetting per-dose cost versus standard factor VIII. Shipment, cold-chain logistics, and concierge coordination add incremental cost; Reserve Meds issues a transparent quote at the start of intake.
Indicative timeline — not guaranteed — for the first shipment after cohort intake opens is approximately 10–21 days from the moment a complete application is submitted to CDSCO. Re-supply is generally faster once the pathway is established.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Altuviiio specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory documentation package for your physician and for CDSCO review.
- Logistics. Cold-chain and temperature-monitored shipment coordination.
- Concierge case lead. A named point of contact for your family and your physician throughout the process.
What we do not do: We are not the prescriber. We do not practice medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating haematologist. We are in pre-launch and operate on a waitlist basis during this phase.
Frequently asked
Is this legal? Yes, when executed through the CDSCO personal-import / named-patient framework with appropriate documentation. See our trust and compliance page.
How does once-weekly compare with my current regimen? Your haematologist is best placed to compare Altuviiio's weekly cadence with your current factor VIII prophylaxis against bleed control and quality-of-life goals. Reserve Meds does not give clinical advice.
What if I develop an inhibitor? Inhibitor surveillance is part of standard haemophilia management and is your haematology team's responsibility. Any inhibitor detection triggers a clinical re-plan.
Can I home-infuse? Many Hemophilia A patients in India already self-infuse or have a trained caregiver who infuses; your haematologist decides if home infusion is appropriate for you.
Will insurance cover any of this? Cash-pay is the default for named-patient imports. Some Indian private insurers and corporate health plans reimburse on case-by-case approval; we supply documentation for your submission but do not process claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Altuviiio coordination.
Add me to the Altuviiio waitlistComposite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.